Sygnature Discovery strengthens management team
4 September 2012
Nottingham-based Sygnature Discovery Limited has announced the
appointment of Colin Sambrook Smith to the newly-created role of Head of
Computational Chemistry and Informatics.
Simon Hirst, Sygnature’s Chief Executive Officer stated, “I am
delighted to welcome Colin to Sygnature Discovery. He is a great
addition to our management team. Colin is an experienced
computational chemist and research manager with a proven ability to
analyse and determine the scientific computing and information
technology needs of research-based organisations.
"He has 26 years of R&D experience mostly within the
pharmaceutical industry. Colin is already contributing his expertise
into several on-going projects and is managing a new,
fully-integrated drug discovery programme for a European biotech
Colin Sambrook Smith added, “I am pleased to have joined
Sygnature Discovery at a time when the company has been experiencing
a huge increase in the demand for its integrated drug discovery
services. Our customers are now mainly undertaking discovery
projects which combine medicinal chemistry, computational chemistry
and in vitro biology/screening at Sygnature, in vitro ADME at
Cyprotex Discovery and pre-clinical experimental services at
Saretius, or Pneumolabs through the ‘federated’ CRO model."